The Role of Nurses in Caring for Patients with Diarrhea from EGFR Inhibitors
Keywords:
the role of nurses, caring for patients with diarrhea, EGFR inhibitorsAbstract
The treatment of non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) gene mutations using EGFR inhibitors has played an increasingly important role. Due to the mechanism of action of the drugs, gastrointestinal side effects often occur, with diarrhea being the most common. If not managed properly, this condition can result in complications. Nurses play a crucial role in the care of these patients as part of the healthcare team. To fulfill this role effectively, they must have a deep understanding of the condition and be able to apply that knowledge in patient care. This article discusses the pathology of diarrhea, the classification of severity, treatment guidelines, and the role of nurses in assessing patients and providing self-care advice regarding diarrhea caused by EGFR inhibitors.
References
Stein A, Voigt W, Jordan K. Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. http://dx.doi.org/101177/1758834009355164[Internet]. 2009 Dec 4 [cited 2024 Sep 6];2:51–63. Available from:https://journals.sagepub.com/doi/abs/10.1177/1758834009355164
Hirsh V. Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr Oncol [Internet]. 2011 [cited 2024 Sep 6];18:126–38. Available from: https://pubmed.ncbi.nlm.nih.gov/21655159/
Maroun JA, Anthony LB, Blais N, Burkes R, Dowden SD, Dranitsaris G, et al. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Current Oncology [Internet]. 2007 [cited 2024 Sep 6];14:13. Available from: /pmc/articles/PMC1891194/
Pessi MA, Zilembo N, Haspinger ER, Molino L, Di Cosimo S, Garassino M, et al. Targeted therapy-induced diarrhea: A review of the literature. Crit Rev Oncol Hematol. 2014 May 1;90:165–79.
Parreira S, Burns K, Moldawer N, Zomordian N, Bandali N, Virdee K, et al. The Role of Nurses in the Management of Adverse Events in Patients Receiving First-Line Axitinib Plus Immuno-Oncology Agents for Advanced Renal Cell Carcinoma. Semin Oncol Nurs. 2024 Feb 1;40:151545.
Uribe JM, Gelbmann CM, Traynor-Kaplan AE, Barrett KE. Epidermal growth factor inhibits Ca(2+)-dependent Cl- transport in T84 human colonic epithelial cells. Am J Physiol [Internet]. 1996 [cited 2024 Sep 6];271(3 Pt 1). Available from: https://pubmed.ncbi.nlm.nih.gov/8843722/
Bowen JM. Mechanisms of TKI-induced diarrhea in cancer patients. Curr Opin Support Palliat Care [Internet]. 2013 Jun [cited 2024 Sep 6];7:162–7. Available from:https://pubmed.ncbi.nlm.nih.gov/23399616/
Tao G, Chityala PK. Epidermal growth factor receptor inhibitor-induced diarrhea: clinical incidence, toxicological mechanism, and management. Toxicol Res (Camb) [Internet]. 2021 Jun 14 [cited 2024 Sep 4];10:476–86. Available from:https://dx.doi.org/10.1093/toxres/tfab026
Management and Mechanisms of Diarrhea Induced by Tyrosine Kinase Inhibitors in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer - Scientific Figure on ResearchGate. Available from: https://www.researchgate.net/figure/Intestinal-dysfunction-chloride-channel-dysfunction-and-inflammation-activation-result_fig3_383243985 [accessed 7 Oct 2024]
Management and Mechanisms of Diarrhea Induced by Tyrosine Kinase Inhibitors in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer - Scientific Figure on ResearchGate. Available from: https://www.researchgate.net/figure/Direct-damage-to-normal-mucous-membranes-Source-Created-with-Biorendercom_fig2_383243985 [accessed 7 Oct 2024]
Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 2017 [cited 2024 Sep 7]; Available from: https://www.meddra.org/
Yang JCH, Reguart N, Barinoff J, Köhler J, Uttenreuther-Fischer M, Stammberger U, et al. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther [Internet]. 2013 Jun [cited 2024 Sep 6];13:729–36. Available from: https://www.tandfonline.com/doi/abs/10.1586/era.13.31
Wang HH, Shieh MJ, Liao KF. A blind, randomized comparison of racecadotril and loperamide for stopping acute diarrhea in adults. World Journal of Gastroenterology: WJG [Internet]. 2005 Mar 3 [cited 2024 Sep 4];11:1540. Available from:/pmc/articles/PMC4305700/
Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev. 2011 Feb 1;37:75–88.
Bossi P, Antonuzzo A, Cherny NI, Rosengarten O, Pernot S, Trippa F, et al. Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. Annals of Oncology [Internet]. 2018 Oct 1 [cited 2024 Sep 7];29:iv126–42. Available from: http://www.annalsofoncology.org/article/S0923753419316941/fulltext
THE TREATMENT OF DIARRHOEA A manual for physicians and other senior health workers World Health Organization.
Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev [Internet]. 2001 [cited 2024 Sep 7];81:1031–64. Available from: https://pubmed.ncbi.nlm.nih.gov/11427691/
Aghsaeifard Z, Heidari G, Alizadeh R. Understanding the use of oral rehydration therapy: A narrative review from clinical practice to main recommendations. Health Sci Rep [Internet]. 2022 Sep 1 [cited 2024 Sep 7];5. Available from: /pmc/articles/PMC9464461/
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Thailand's National Cancer Institute Foundation
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความทีตีพิมพ์ในวารสารโรคมะเร็งนี้ถือว่าเป็นลิขสิทธิ์ของมูลนิธิสถาบันมะเร็งแห่งชาติ และผลงานวิชาการหรือวิจัยของคณะผู้เขียน ไม่ใช่ความคิดเห็นของบรรณาธิการหรือผู้จัดทํา
